11 drug(s) with this reaction
5,218 total reports
Gastrooesophageal Reflux Disease has been reported as an adverse reaction across 11 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 5,218 adverse event reports mention gastrooesophageal reflux disease in connection with Haleon Us Holdings Llc products.
This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with gastrooesophageal reflux disease, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Haleon Us Holdings Llc drugs have gastrooesophageal reflux disease listed in their FDA adverse event reports, sorted by report count:
In addition to gastrooesophageal reflux disease, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:
11 drug(s) manufactured by Haleon Us Holdings Llc have gastrooesophageal reflux disease listed in their FDA adverse event reports: CALCIUM CARBONATE, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, and others.
There are a combined 5,218 reports of gastrooesophageal reflux disease across 11 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.